A Study of Hydroxycholoroquine Compared to Placebo as Treatment for People With COVID-19

Exclusion Criteria

• •Prior receipt of hydroxychloroquine for treatment or prophylaxis of SARS-CoV-2 or patient is taking hydroxychloroquine for other approved indications (e.g., lupus, rheumatoid arthritis)
• •No documented SARS-CoV-2 infection
• •Mechanical ventilation
• •Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives Preexisting retinopathy documented in medical history
• •Pregnancy or Breastfeeding
• •Concurrent use of any other quinine derivative (chloroquine, mefloquine) or rifamycins (rifampin, rifabutin)
• •Antiarrhythmic medications (amiodarone, sotalol, dofetilide, procainamide, quinidine, flecainide)
• •History of glucose-6-phosphate dehydrogenase deficiency
• •Pre-treatment corrected QT interval (QTc) \>500 milliseconds
• •Pressor requirement to maintain blood pressure
• •Alanine aminotransferase (ALT) and/or asparate aminotransferase (AST) level \> 5X upper limit of normal
• •Creatinine clearance \<30 mL/min or requirement of dialysis or continuous venovenous hemofiltration
• •Concomitant participation in a therapeutic trial for SARS-CoV-2 or receiving any experimental treatment for SARS-CoV-2 within 7 days of randomization
• •Any condition that in the opinion of the principal investigator would prevent participation in the trial or would interfere with the trial endpoints